comparemela.com
Home
Live Updates
ALPINE: After 39 Months, Zanubrutinib Keeps Its PFS Edge Over Ibrutinib in R/R CLL; Especially for High-Risk Patients : comparemela.com
ALPINE: After 39 Months, Zanubrutinib Keeps Its PFS Edge Over Ibrutinib in R/R CLL; Especially for High-Risk Patients
Extended follow-up data presented at the American Society of Hematology show the advantage seen a year ago has held up for the second-generation BTK inhibitor.
Related Keywords
United States
,
California
,
San Diego
,
American
,
Jenniferr Brown
,
,
Health Savings
,
Dana Farber Cancer Institute Image
,
American Society Of Hematology
,
Dana Farber Cancer Institute
,
American Society
,
Annual Meeting
,
American Journal
,
New England Journal
,
Potential Health
,
Life Over
,
Zanubrutinib
,
Ibrutinib
,
Btk Inhibitor
,
Cll
,
Brukinsa
,
Beigene
,
Dana Farber
,
Alpine
,
comparemela.com © 2020. All Rights Reserved.